Eiger Pharmaceuticals Reports Results of Lambda in P-II LIMT (Lambda MonoTx) Study in Hepatitis Delta Virus (HDV) Infection

 Eiger Pharmaceuticals Reports Results of Lambda in P-II LIMT (Lambda MonoTx) Study in Hepatitis Delta Virus (HDV) Infection

Eiger Pharmaceuticals Reports Results of Lambda in P-II LIMT (Lambda MonoTx) Study in Hepatitis Delta Virus (HDV) Infection

Shots:

  • The P-II LIMT study involves assessing of (peg INF-Lambda) Lambda 120/180 μg SC IV qw for 48wks. in ratio (1:1) (N=33) in patients with chronic HDV, testing safety, efficacy & tolerability. In the study, patients received continuous anti-hepatitis B virus nucleos(t)ide analog
  • P-II LIMT study results (120/180mg): mean decline in HDV-RNA (-1.5 log10, -2.4 log10), ≥2 log10 decline (42.9%, 60%); HDV-RNA -ve at end of treatment (14.3%, 40%)
  • In 2016, Eiger gained global rights to Lambda from BMS. Additionally, P-II LIFT (Lambda InterFeron combo-Therapy) is conducted at NIH assessing Lambda + Lonafarnib boosted with Ritonavir with 1EP ≥ 2 log decline in HDV RNA & 2EP > 2 point improvement in histological activity index and no progression in fibrosis

Click here to read full press release/ article | Ref: Eiger Pharmaceuticals | Image: RTE

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post